The Drug Stock Higher on Asset Sale Rumors

TEVA stock has been on the rebound since November

Managing Editor
Dec 26, 2017 at 9:58 AM
facebook twitter linkedin

Drugmaker Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has had a rocky year, culminating in drastic cuts to its workforce and suspended dividend payments. Today, the stock is generating buzz amid reports that Israel's biggest pharmacy chain, Super-Pharm, is in talks to buy a Teva plant. Below, we take a closer look at TEVA stock.

Super-Pharm will reportedly pay between $17 - $23 million for the Ashdod-based plant, and would continue to employ the plant's 70 workers. The news has sent TEVA stock up 2.8% to trade at $19.26 this morning, on pace for its highest close since mid-September. Since falling to a 17-year low of $10.85 on Nov. 2, TEVA has tacked on 78%.

Despite the equity's solid rebound over the past couple of months, analysts remain pessimistic. Of the 23 brokerage firms covering the drug name, 20 rate TEVA shares a "hold" or worse. However, recent options buyers have been upping the bullish ante. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock's 50-day call/put volume ratio of 1.73 is higher than 87% of all other readings from the past year.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners